PREConsumer Defensive · Packaged FoodsThe 3 Wall Street analysts covering Prenetics Global Ltd. hold a median 12-month price target of $35 — +73.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Prenetics Global Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (90): The shares have been drifting up relative to others.
Value (12): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRE, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +73.3% from it.
Of the 20 most recent actions, 8 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 July 2026 | Benchmark | Maintains | Buy | $30 → $40 |
| 16 June 2026 | Benchmark | Initiates | Buy | — |
| 16 Mar 2026 | Lake Street | Initiates | Buy | — |
| 29 Oct 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 16 Jan 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 4 Dec 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 4 Apr 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 26 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | $4.00 |
| 19 Sept 2023 | Cantor Fitzgerald | Maintains | Overweight | $6.00 → $4.00 |
| 22 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 18 Jan 2023 | Cantor Fitzgerald | Initiates | Overweight | $7.00 |
| 28 July 2015 | Barclays | Maintains | Overweight | $137 → $140 |
| 9 July 2015 | Deutsche Bank | Maintains | Hold | $6.50 → $6.10 |
| 18 June 2015 | Keefe, Bruyette & Woods | Maintains | Market Perform | $138 → $140 |
| 13 May 2015 | BMO Capital | Maintains | Market Perform | $130 → $138 |
| 6 May 2015 | Deutsche Bank | Maintains | Hold | $6.10 → $6.50 |
| 22 Apr 2015 | UBS | Downgrade | Neutral | — |
| 20 Apr 2015 | Deutsche Bank | Maintains | Hold | $125 → $130 |
| 17 Apr 2015 | BMO Capital | Downgrade | Market Perform | $122 → $130 |
| 26 Mar 2015 | BMO Capital | Upgrade | Outperform | $114 → $122 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 54% of US stocks
Cheaper than 32% of US stocks
Cheaper than 75% of US stocks
Higher than 96% of US stocks
Higher than 85% of US stocks
Higher than 78% of US stocks
Higher than 17% of US stocks
Higher than 13% of US stocks
Higher than 22% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Prenetics Global Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Prenetics Global Limited (PRE) held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.
Why it matters — The earnings call transcript provides PRE watchers with insight into the company's latest quarterly results and management commentary.
Prenetics' IM8 announced a multi-year global partnership with actress and producer Lily Collins, who becomes IM8's first Global Ambassador from film and television and a shareholder in Prenetics. The announcement coincided with Prenetics raising its FY 2026 revenue guidance to $220+ million and initiating FY 2027 guidance of $400+ million.
Why it matters — PRE watchers would care because the partnership expands IM8's brand reach into global entertainment and culture while the company simultaneously raised its revenue guidance.
Prenetics Global reported second-quarter revenue of $46.5 million, up 29% sequentially and roughly 3.9 times from a year earlier, driven by its IM8 supplement business adding subscribers and scaling marketing. The company raised its full-year revenue outlook and said July marked its first month of positive consolidated adjusted free cash flow, including funding under its General Catalyst facility.
Why it matters — A Prenetics watcher would care because the company raised its full-year revenue outlook and achieved its first month of positive adjusted free cash flow, signaling improved growth and financial traction.
Prenetics' IM8 segment reported Q2 2026 revenue growth of 288% year-over-year, and the company raised its FY 2026 IM8 revenue guidance to $220–230 million. July marked the first month of positive consolidated adjusted free cash flow, which is expected to remain positive through Q3 and beyond.
Why it matters — A PRE watcher would care because strong IM8 growth, raised guidance, and the shift to positive cash flow indicate improving financial momentum for the company.
Prenetics, the parent of IM8, announced the appointment of Caroline Levy, a veteran Wall Street equity research analyst with over 30 years' experience, as an independent director. She will serve on the Audit, Compensation, and Nominating and Corporate Governance committees. The company also said it will report its second quarter 2026 financial results on Tuesday, August 18, 2026, and host a live earnings webcast at 8:30 a.m.
Why it matters — The addition of a highly experienced consumer analyst to independent board and key committees strengthens governance oversight just ahead of the company's upcoming earnings report.
The 3 Wall Street analysts covering Prenetics Global Ltd. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Prenetics Global Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prenetics Global Ltd. 48 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Prenetics Global Ltd. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +73.3% from the last close, and Ticker Nerd's factor model ranks Prenetics Global Ltd. 48 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Prenetics Global Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.
Prenetics Global Limited is a health sciences company headquartered in Hong Kong that specializes in early detection, prevention, and treatment of diseases, particularly cancer, through genomic testing and wellness solutions. The company operates three primary business segments: Prevention, through CircleDNA, a direct-to-consumer genetic testing brand utilizing next-generation sequencing technology to provide comprehensive health and wellness insights; Diagnostics, through ACT Genomics, which offers precision oncology testing services and became the first Asia-based company to receive FDA clearance for comprehensive genomic profiling of solid tumors; and Consumer Health, featuring IM8 Health, a supplement and wellness brand, and Europa, a sports nutrition distribution company.
The most recent item we track (Seeking Alpha, 22 Aug 2026): "Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript". Prenetics Global Limited (PRE) held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.
Prenetics Global Limited is a health sciences company headquartered in Hong Kong that specializes in early detection, prevention, and treatment of diseases, particularly cancer, through genomic testing and wellness solutions. The company operates three primary business segments: Prevention, through CircleDNA, a direct-to-consumer genetic testing brand utilizing next-generation sequencing technology to provide comprehensive health and wellness insights; Diagnostics, through ACT Genomics, which offers precision oncology testing services and became the first Asia-based company to receive FDA clearance for comprehensive genomic profiling of solid tumors; and Consumer Health, featuring IM8 Health, a supplement and wellness brand, and Europa, a sports nutrition distribution company. Prenetics' consumer DNA tests use whole-exome sequencing, providing significantly more genetic data than traditional array-based methods. The company distributes its products globally through retail partnerships, online platforms, and healthcare providers across Hong Kong, Taiwan, the United States, and other international markets, serving individual consumers, healthcare professionals, and institutions seeking science-backed solutions for health optimization and disease management.
CEO Mr. Sheng Wu Yeung · 98 employees · Hong Kong · https://www.prenetics.com